Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a key therapeutic option in the management of type 2 diabetes mellitus (T2DM), owing to their efficacy in lowering blood glucose, in addition to providing cardiovascular and renal benefits, and ameliorating metabolic syndrome, as supported by a wealth of evidence-based research (Davies et al., 2022). The gene discussed is GLP1R; the disease is metabolic syndrome.